About Us

Contact Us

Add Favorite
Home About Us Product News Order Career Contact

                                                                                                            

           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd 

           

             

 

Product Indentification
 

 

Name:   INCB18424
Synonyms:   INCB-018424.  Ruxolitinib phosphate. Chemical name: 1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)-,
CAS Registry Number:   1160597-27-2
Molecular Formula:   C17H18N6
Molecular Weight:    306.36
Molecular Structure:    

 

 

                   Purity:98%min

 

 

                   Storage: 4 deg C

 

 

                  Inquiry (H1NMR,HPLC,LC-MS)

 

 

Information about this agent:

Ruxolitinib (INCB-018424) is a selective tyrosine-protein kinase JAK1 and JAK2 inhibitor that acts by blocking the JAK/STAT pathway. Ruxolitinib is being developed as an oral formulation for the treatment of several diseases, showing a good safety profile without off-target toxicities. The compound showed promising results in early clinical studies in myeloproliferative neoplasms and is currently in phase III clinical development for the treatment of myelofibrosis, either primary or secondary to polycythemia or essential thrombocythemia. Ruxolitinib is also being evaluated in phase II clinical trials for the treatment of polycythemia vera, essential thrombocythemia and secondary, post-myeloproliferative disorder acute myeloid leukemia. Its potential efficacy is being tested in other leukemias, as well as in prostate cancer and multiple myeloma. This novel JAK1/2 inhibitor is also being used topically for the treatment of psoriasis in phase II studies, and it was studied for the treatment of rheumatoid arthritis but development in this indication has been discontinued. (source: Drugs of the Future.2010, 35(6): 457).



Current developer: Incyte Corp and Novartis AG

References

1. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs. 2010 Jun;13(6):394-403.



2. Drugs of the Future.2010, 35(6): 457
 

 

 

 

Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved
 

 

 

No_Right_Click

 

No_Right_Click